Observational Post-Authorization Study of Patients Treated With Raltegravir
The purpose of this study is to assess the phase IV safety of raltegravir, an integrase inhibitor recently released for use as an HIV antiretroviral medication, in the course of ordinary clinical practice in Kaiser Permanente Northern and Southern California.
Funder: Merck and Co., Inc.
Principal Investigator: Horberg, Michael
Impact of Missed Office Visits on HIV Outcomes and Mortality
This study will investigate if the frequency of missed visits during the first year after new HIV diagnosis predicts HIV-related outcomes after that year, as has been seen in public care settings.
Funder: Kaiser Permanente Community Benefit Program
Principal Investigator: Horberg, Michael
Developing an HIV-Specific Prevention Index Using the Electronic Medical Record
The overarching objective of this study is to assess in HIV-infected patients, the degree of association between successful general clinical care by HIV disease-treating providers (reflected in overall adherence to recommended general prevention and screening guidelines) and higher-quality HIV-specific care and related outcomes. The study sample includes nearly 4,900 HIV-infected patients in three Kaiser Permanente (KP) regions (Northwest, Northern California, and Southern California) who received their initial HIV infection diagnosis between 1/1/03 and 12/31/07
Funder: Agency for Healthcare Research and Quality
Principal Investigator: Horberg, Michael
Optimizing Multidisciplinary HIV Care Team for Maximal HAART Adherence
Optimizing Multidisciplinary HIV Care Team for Maximal HAART Adherence
Funder: Kaiser Foundation Research Institute
Principal Investigator: Horberg, Michael
Optimizing Multidisciplinary HIV Care Team for Max
Retrospective cohort study to determine optimized HIV multidisciplinary care team to maximize HAART adherence and other HIV outcomes and minimize urgent care utilization.
Funder: National Institute of Mental Health
Principal Investigator: Horberg, Michael
Gilead Modern Haart
This retrospective cohort study, using data from Kaiser Permanente, determines the predictors of initiating HAART therapy in the modern treatment era and has that changed over time.
Funder: Gilead, Inc.
Principal Investigator: Horberg, Michael
Considerations of Emerging Issues in the Treatment of HIV ("CEITH")
This interregional study investigates the epidemiology of advanced treatment failure among HIV-infected patients, the utilization of a new class of antiretroviral medications, and the impact of low level viremia on HIV-infected patients being treated with antiretorivral therapy.
Funder: Merck and Co., Inc.
Principal Investigator: Horberg, Michael
North America AIDS Cohorts Collaboration on Research and Disease (NA-ACCORD)
This study's intent is to perform HIV-related analyses that cannot be accomplished with limited power of individual cohorts or could not be reasonably accomplished by clinical trials. These analyses will be achieved by combining collaborative HIV cohort data (including Kaiser Permanente Northern California) to achieve appropriate power and analyses that could simulate randomized trials where appropriate.
Funder: Nat. Inst. of Allergy and Infectious Diseases
Principal Investigator: Horberg, Michael
Economic Implications of Care of HIV-Positive Patients With Multi-drug Resistance Within a Managed Care Population
This retrospective study uses cost and other data from Kaiser Permanente to determine the added overall cost of patients who are on their third (or likely greater) HAART regimen compared to antiretroviral naive patients beginning their first regimen in the modern HIV treatment era.
Funder: Abbott
Principal Investigator: Horberg, Michael
United States Post-Licensure Safety (ISENTRESS™)
Five-year surveillance data study to assess safety of new antiretroviral medication raltegravir, with comparisons to rates among similar HIV-infected patients taking antiretroviral medications other than raltegravir.
Funder: Merck and Co., Inc.
Principal Investigator: Horberg, Michael
Treatment Regimen, Provider, and Clinical Characteristics Associated with Receipt of HAART: An Analysis from Kaiser Permanente
This retrospective cohort study, using Kaiser Permanente data, determines the predictors of initiating HAART therapy in the modern treatment era and if they have changed over time.
Funder: Gilead, Inc.
Principal Investigator: Horberg, Michael
Effect of Tenofovir on Renal Function--An Observational Cohort Study
This study seeks to determine the incidence of change in renal function of patients taking Tenofovir (TDF) and compare that to patients on other NRTI.
Funder: Gilead, Inc.
Principal Investigator: Horberg, Michael
Retrospective Review of Atazanavir Experience in Kaiser Permanente
This study will investigate the Kaiser Permanente experience with Atazanavir (ATV) to see what the success has been with a HAART regimen employing ATV.
Funder: Bristol-Myers Squibb
Principal Investigator: Horberg, Michael
Epidemiology and Clinical Outcome of HIV/HCV Co-Infection
This study uses the administrative databases within the Department of Veterans Affairs and Kaiser Permanente Health Care systems to determine the number of human immunodeficiency virus (HIV) infected patients, number of HIV/Hepatitis C virus (HCV) co-infected patients, their demographic and clinical characteristics, and co-morbid conditions that affect survival.
Funder: GMF
Principal Investigator: Horberg, Michael